Mostrar el registro sencillo del ítem

dc.contributor.authorRotolo, Renee
dc.contributor.authorDragacevic, Vladimir
dc.contributor.authorKalaba, Predrag
dc.contributor.authorUrban, Ernst
dc.contributor.authorZehl, Martin
dc.contributor.authorRoller, Alexander
dc.contributor.authorWackerlig, Judith
dc.contributor.authorLanger, Thierry
dc.contributor.authorPistis, Marco
dc.contributor.authorDe Luca, Maria Antonietta
dc.contributor.authorCaria, Francesca
dc.contributor.authorSchwartz, Rebecca
dc.contributor.authorPresby, Rose
dc.contributor.authorYang, Jen-Hau
dc.contributor.authorSamels, Shanna
dc.contributor.authorCorrea, Merce
dc.contributor.authorLubec, Gert
dc.contributor.authorSalamone, John
dc.date.accessioned2019-12-10T11:49:34Z
dc.date.available2019-12-10T11:49:34Z
dc.date.issued2019-06-28
dc.identifier.citationROTOLO, Renee;DRAGACEVIC, Vladimir; KALABA, Predrag; URBAN, Ernst; ZEHL, Martin; ROLLER, Alexander; WACKERLIG, Judith; LANGER, Thierry; PISTIS, Marco; DE LUCA, Maria Antonietta; CARIA, Francesca; SCHWARTZ, Rebecca; PRESBY, Rose; YANG, Jen-Hau; SAMELS, Shanna; CORREA SANZ, Mercé; LUBEC, Gert; SALAMONE, John D. (2019). The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding. Frontiers in Pharmacology, v. 10ca_CA
dc.identifier.urihttp://hdl.handle.net/10234/185349
dc.description.abstractAnimal studies of effort-based choice behavior are being used to model effort-related motivational dysfunctions in humans. With these procedures, animals are offered a choice between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/ low reward options. Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine transport blocker tetrabenazine, which inhibits DA storage. Because many drugs that block DA transport act as major stimulants that also release DA, and produce a number of undesirable side effects, there is a need to develop and characterize novel atypical DA transport inhibitors. (S)-CE-123 ((S)-5-((benzhydrylsulfnyl) methyl)thiazole) is a recently developed analog of modafnil with the biochemical characteristics of an atypical DA transport blocker. The present paper describes the enantioselective synthesis and initial chemical characterization of (S)-CE-123, as well as behavioral experiments involving effort-based choice and microdialysis studies of extracellular DA. Rats were assessed using the fxed ratio 5/chow feeding choice test. Tetrabenazine (1.0 mg/kg) shifted choice behavior, decreasing lever pressing and increasing chow intake. (S)-CE-123 was coadministered at doses ranging from 6.0 to 24.0 mg/kg, and the highest dose partially but signifcantly reversed the effects of tetrabenazine, although this dose had no effect on fxed ratio responding when administered alone. Additional experiments showed that (S)-CE-123 signifcantly increased lever pressing on a progressive ratio/chow feeding choice task and that the effective dose (24.0 mg/kg) increased extracellular DA in nucleus accumbens core. In summary, (S)-CE-123 has the behavioral and neurochemical profle of a compound that can block DA transport, reverse the effort-related effects of tetrabenazine, and increase selection of high-effort progressive ratio responding. This suggests that (S)-CE- 123 or a similar compound could be useful as a treatment for effort-related motivational dysfunction in humans.ca_CA
dc.format.extent12 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherFrontiers Mediaca_CA
dc.relation.isPartOfFrontiers in Pharmacology (2019), v. 10ca_CA
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-sa/4.0/*
dc.subjectDopamineca_CA
dc.subjectTransportca_CA
dc.subjectSynthesisca_CA
dc.subjectMotivationca_CA
dc.subjectDepressionca_CA
dc.subjectFatigueca_CA
dc.subjectAnergiaca_CA
dc.subjectModafnilca_CA
dc.titleThe Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Respondingca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttps://doi.org/10.3389/fphar.2019.00682
dc.relation.projectIDFondazione di Sardegna (Esercizio finanziario 2017), FIR 2019, Fondo di Sviluppo e Coesione 2014-2020(Project RASSR03071; CUP F76C18000830002).ca_CA
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttps://www.frontiersin.org/articles/10.3389/fphar.2019.00682/fullca_CA
dc.contributor.funder1) University of Connecticut Research Foundation; 2) Connecticut Institute for Brain and Cognitive Sciences and the Summer Undergraduate Research Fund at the University of Connecticut; 3) University of Connecticut Psychological Sciences Department;ca_CA
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_CA


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional